In addition, the most recent CAR-T cell therapy approved, idecabtagene vicleuce, targets B-cell maturation antigen (BCMA; expressed on plasma cells) in patients with multiple myeloma. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.